ClearPoint Neuro Inc vs Nerdwallet Inc — how do they compare? ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M), while Nerdwallet Inc trades at $9.78 (market cap $625.17M). The key difference: Nerdwallet Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| CLPT | NRDS | |
|---|---|---|
Market Cap | $454.21M | $625.17M |
Sector | Health | Financials |
52-Week High | $29.60 | $15.93 |
52-Week Low | $8.66 | $7.58 |
Enterprise Value | $488.79M | $539.47M |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →